LTPA2022523I1 - - Google Patents

Info

Publication number: LTPA2022523I1
Authority: LT; Lithuania

Application number

LTPA2022523C

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-05-15

Filing date

2022-11-10

Publication date

2022-12-12

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48670630&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LTPA2022523(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2022-11-10 Application filed by Novartis Ag filed Critical Novartis Ag

2022-12-12 Publication of LTPA2022523I1 publication Critical patent/LTPA2022523I1/lt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/576—Six-membered rings
- C07F9/58—Pyridine rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Oncology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Hematology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Pyridine Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Plural Heterocyclic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Medicinal Preparation (AREA)
Hydrogenated Pyridines (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

LTPA2022523C 2012-05-15 2022-11-10 LTPA2022523I1 (lt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201261647174P	2012-05-15	2012-05-15
US201361790967P	2013-03-15	2013-03-15
PCT/IB2013/053768 WO2013171639A1 (en)	2012-05-15	2013-05-09	Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1

Publications (1)

Publication Number	Publication Date
LTPA2022523I1 true LTPA2022523I1 (lt)	2022-12-12

Family

ID=48670630

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
LTEP13730652.8T LT2861579T (lt)	2012-05-15	2013-05-09	Benzamido dariniai, skirti abl1, abl2 ir bcr-abl1 aktyvumo inhibavimui
LTPA2022523C LTPA2022523I1 (lt)	2012-05-15	2022-11-10

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
LTEP13730652.8T LT2861579T (lt)	2012-05-15	2013-05-09	Benzamido dariniai, skirti abl1, abl2 ir bcr-abl1 aktyvumo inhibavimui

Country Status (50)

Country	Link
US (2)	US8829195B2 (lt)
EP (1)	EP2861579B9 (lt)
JP (1)	JP6078639B2 (lt)
KR (1)	KR102091893B1 (lt)
CN (1)	CN104302638B (lt)
AP (1)	AP3613A (lt)
AR (1)	AR091063A1 (lt)
AU (1)	AU2013261127B2 (lt)
BR (1)	BR112014026383B1 (lt)
CA (1)	CA2868958C (lt)
CL (1)	CL2014002757A1 (lt)
CO (1)	CO7131380A2 (lt)
CR (1)	CR20140519A (lt)
CU (1)	CU24265B1 (lt)
CY (2)	CY1120235T1 (lt)
DK (1)	DK2861579T5 (lt)
DO (1)	DOP2014000256A (lt)
EA (1)	EA024391B1 (lt)
ES (1)	ES2670601T3 (lt)
FR (1)	FR22C1053I2 (lt)
GE (1)	GEP201606532B (lt)
GT (1)	GT201400253A (lt)
HK (1)	HK1203495A1 (lt)
HR (1)	HRP20180695T1 (lt)
HU (2)	HUE039138T2 (lt)
IL (1)	IL235566A (lt)
JO (1)	JO3453B1 (lt)
LT (2)	LT2861579T (lt)
MA (1)	MA37519B1 (lt)
ME (1)	ME03095B (lt)
MX (1)	MX359014B (lt)
MY (1)	MY169377A (lt)
NL (1)	NL301201I2 (lt)
NO (1)	NO2022043I1 (lt)
NZ (1)	NZ701626A (lt)
PE (3)	PE20150669A1 (lt)
PH (1)	PH12014502531B1 (lt)
PL (1)	PL2861579T3 (lt)
PT (1)	PT2861579T (lt)
RS (1)	RS57177B1 (lt)
SG (1)	SG11201407152XA (lt)
SI (1)	SI2861579T1 (lt)
SV (1)	SV2014004850A (lt)
TN (1)	TN2014000427A1 (lt)
TR (1)	TR201807023T4 (lt)
TW (1)	TWI560183B (lt)
UA (1)	UA113208C2 (lt)
UY (1)	UY34811A (lt)
WO (1)	WO2013171639A1 (lt)
ZA (1)	ZA201407065B (lt)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RS56395B1 (sr)	2012-04-26	2017-12-29	Bristol Myers Squibb Co	Derivati imidazotiadiazola i imidazopirazina kao inhibitori proteazom aktiviranog receptora 4 (par4) za lečenje agregacije trombocita
EP2861579B9 (en)	2012-05-15	2018-08-29	Novartis AG	Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1
CA2871332A1 (en) *	2012-05-15	2013-11-21	Novartis Ag	Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1
CN104334529B (zh)	2012-05-15	2017-03-15	诺华股份有限公司	用于抑制abl1、abl2和bcr‑abl1的活性的化合物和组合物
WO2013171642A1 (en)	2012-05-15	2013-11-21	Novartis Ag	Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1
TWI568722B (zh)	2012-06-15	2017-02-01	葛蘭馬克製藥公司	作爲ｍＰＧＥＳ－１抑制劑之三唑酮化合物
ES2649156T3 (es)	2013-01-14	2018-01-10	Incyte Holdings Corporation	Compuestos bicíclicos de carboxamida aromática útiles como inhibidores de quinasas Pim
SG10201705662WA (en)	2013-01-15	2017-08-30	Incyte Corp	Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors
MX2016002367A (es)	2013-08-23	2016-10-28	Incyte Corp	Compuestos de carboxamida de furo y tienopiridina utiles como inhibidores de cinasas pim.
JPWO2015064764A1 (ja) *	2013-11-01	2017-03-09	宇部興産株式会社	アリーロイル（オキシ又はアミノ）ペンタフルオロスルファニルベンゼン化合物、薬学的に許容されるその塩、及びそのプロドラッグ
JOP20200094A1 (ar)	2014-01-24	2017-06-16	Dana Farber Cancer Inst Inc	جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar)	2014-01-31	2017-06-16	Children’S Medical Center Corp	جزيئات جسم مضاد لـ tim-3 واستخداماتها
JP2017512183A (ja) *	2014-02-13	2017-05-18	リガンド・ファーマシューティカルズ・インコーポレイテッド	プロドラッグ化合物およびそれらの使用
CR20160425A (es)	2014-03-14	2017-05-26	Novartis Ag	Moléculas de anticuerpos que se unen a lag-3 y usos de las mismas
CN106687118A (zh)	2014-07-02	2017-05-17	配体药物公司	前药化合物及其用途
US9580418B2 (en)	2014-07-14	2017-02-28	Incyte Corporation	Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
US9822124B2 (en)	2014-07-14	2017-11-21	Incyte Corporation	Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors
MA41044A (fr)	2014-10-08	2017-08-15	Novartis Ag	Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
ES2952717T3 (es)	2014-10-14	2023-11-03	Novartis Ag	Moléculas de anticuerpos contra PD-L1 y usos de las mismas
EP3233918A1 (en)	2014-12-19	2017-10-25	Novartis AG	Combination therapies
CN104478911A (zh) *	2014-12-19	2015-04-01	成都安斯利生物医药有限公司	一种制备3-三氟甲基吡咯硼酸的方法
CN113181362B (zh) *	2015-01-13	2023-06-13	国立大学法人京都大学	用于预防和/或治疗肌萎缩性侧索硬化症的药剂
KR20170129802A (ko)	2015-03-10	2017-11-27	아두로 바이오테크, 인코포레이티드	＂인터페론 유전자의 자극인자＂-의존적 신호전달을 활성화하는 조성물 및 방법
WO2016196244A1 (en)	2015-05-29	2016-12-08	Incyte Corporation	Pyridineamine compounds useful as pim kinase inhibitors
WO2017019896A1 (en)	2015-07-29	2017-02-02	Novartis Ag	Combination therapies comprising antibody molecules to pd-1
US20180340025A1 (en)	2015-07-29	2018-11-29	Novartis Ag	Combination therapies comprising antibody molecules to lag-3
US20180207273A1 (en)	2015-07-29	2018-07-26	Novartis Ag	Combination therapies comprising antibody molecules to tim-3
AR105967A1 (es)	2015-09-09	2017-11-29	Incyte Corp	Sales de un inhibidor de pim quinasa
TW201718546A (zh)	2015-10-02	2017-06-01	英塞特公司	適用作pim激酶抑制劑之雜環化合物
AU2016350700A1 (en)	2015-11-03	2018-05-17	Janssen Biotech, Inc.	Antibodies specifically binding PD-1 and TIM-3 and their uses
CA3007671A1 (en)	2015-12-17	2017-06-22	Novartis Ag	Antibody molecules to pd-1 and uses thereof
US9931342B2 (en)	2016-02-02	2018-04-03	Duke University	Compositions and methods for the treatment of cancer
EP3448852A4 (en) *	2016-04-29	2019-04-10	Astar Biotech LLC	NOVEL HETEROCYCLIC COMPOUNDS AS INHIBITORS OF TYROSINE KINASE BCR-ABL
EP3507367A4 (en)	2016-07-05	2020-03-25	Aduro BioTech, Inc.	CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF
US20200017482A1 (en) *	2016-09-27	2020-01-16	Novartis Ag	Surfactant systems for crystallization of organic compounds
US20190240176A1 (en) *	2016-10-26	2019-08-08	The University Of Georgia Research Foundation, Inc.	Methods of treatment for myeloid leukemia
EP3596049A4 (en) *	2017-03-15	2021-01-13	Sun Pharma Advanced Research Company Limited	NEW AMORPHIC DISPERSION OF CYCLOPROPANECARBOXYLIC ACID (5- {5- [N '- (2-CHLORO-6-METHYLBENZOYL) HYDRAZINOCARBONYL] -2-METHYL-PHENYLETHYNYL} -PYRIDIN-2-AMIDE
UY37695A (es)	2017-04-28	2018-11-30	Novartis Ag	Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
JPWO2018216705A1 (ja) *	2017-05-23	2020-03-26	国立大学法人京都大学	神経変性疾患の予防及び／又は治療剤
WO2018237173A1 (en)	2017-06-22	2018-12-27	Novartis Ag	ANTIBODY MOLECULES DIRECTED AGAINST CD73 AND CORRESPONDING USES
US10596161B2 (en)	2017-12-08	2020-03-24	Incyte Corporation	Low dose combination therapy for treatment of myeloproliferative neoplasms
JP2021509907A (ja)	2018-01-09	2021-04-08	リガンド・ファーマシューティカルズ・インコーポレイテッド	アセタール化合物およびその治療的使用
EP3781156A4 (en) *	2018-04-16	2022-05-18	C4 Therapeutics, Inc.	SPIROCYCLIC COMPOUNDS
UY38247A (es)	2018-05-30	2019-12-31	Novartis Ag	Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
KR102618168B1 (ko) *	2018-07-06	2023-12-27	일양약품주식회사	프리온 질환의 예방 또는 치료를 위한 약제학적 조성물
KR102119150B1 (ko) *	2018-10-23	2020-06-04	한국원자력의학원	N-1h-벤지미다졸-2-일-3-(1h-피롤-1-일) 벤자미드를 유효성분으로 함유하는 암 예방 또는 치료용 약학적 조성물
US11407735B2 (en) *	2019-05-16	2022-08-09	Novartis Ag	Crystalline forms of N-[4-(Chlorodifluoromethoxy)phenyl]-6-[(3R)-3-hydroxypyrrolidin-1-yl]-5-(1H-pyrazol-5-yl)pyridine-3-carboxamide
US11236070B2 (en) *	2019-05-16	2022-02-01	Novartis Ag	Chemical process
GB201913110D0 (en) *	2019-09-11	2019-10-23	Benevolentai Bio Ltd	New compounds and methods
JP2022548881A (ja)	2019-09-18	2022-11-22	ノバルティスアーゲー	Ｅｎｔｐｄ２抗体、組合せ療法並びに抗体及び組合せ療法を使用する方法
WO2021143927A1 (zh) *	2020-01-19	2021-07-22	正大天晴药业集团股份有限公司	作为bcr-abl抑制剂的化合物
WO2021154980A1 (en)	2020-01-28	2021-08-05	Teva Pharmaceuticals International Gmbh	Solid state forms of asciminib and processes for the preparation thereof
US20230072528A1 (en)	2020-02-05	2023-03-09	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for discontinuing a treatment with a tyrosine kinase inhibitor (tki)
CN111321200A (zh) *	2020-02-28	2020-06-23	广州安镝声生物医药科技有限公司	一种细胞外abl1激酶活性检测试剂盒及其应用
CN115124551B (zh) *	2021-03-24	2024-04-30	奥锐特药业(天津)有限公司	一种高纯度米哚妥林的制备方法
WO2022206937A1 (zh) *	2021-04-01	2022-10-06	苏州晶云药物科技股份有限公司	一种吡唑取代的烟酰胺类化合物的盐酸盐新晶型及其制备方法
JP2024518426A (ja)	2021-05-11	2024-05-01	ノバルティスアーゲー	投与レジメン
CA3219641A1 (en)	2021-05-28	2022-12-01	Yinsheng ZHANG	Compound used as bcr-abl inhibitor
CN114149409B (zh) *	2021-11-16	2024-03-22	中国药科大学	一种具有蛋白激酶抑制活性的（杂）芳基酰胺类化合物
CN116135851A (zh) *	2021-11-17	2023-05-19	武汉众诚康健生物医药科技有限公司	一种芳香胺化合物及其应用
EP4447968A2 (en) *	2021-12-13	2024-10-23	The Regents Of The University Of California	Abl inhibitors and uses thereof
CN115109048B (zh) *	2022-08-10	2023-12-08	中国药科大学	一种(杂)芳基酰胺类化合物
WO2024100212A1 (en)	2022-11-10	2024-05-16	Synthon B.V.	Crystalline form of asciminib hydrochloride

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CH445129A (fr)	1964-04-29	1967-10-15	Nestle Sa	Procédé pour la préparation de composés d'inclusion à poids moléculaire élevé
US3459731A (en)	1966-12-16	1969-08-05	Corn Products Co	Cyclodextrin polyethers and their production
US3426011A (en)	1967-02-13	1969-02-04	Corn Products Co	Cyclodextrins with anionic properties
US3453257A (en)	1967-02-13	1969-07-01	Corn Products Co	Cyclodextrin with cationic properties
US3453259A (en)	1967-03-22	1969-07-01	Corn Products Co	Cyclodextrin polyol ethers and their oxidation products
US4235871A (en)	1978-02-24	1980-11-25	Papahadjopoulos Demetrios P	Method of encapsulating biologically active materials in lipid vesicles
DE2845997A1 (de)	1978-10-23	1980-04-30	Bayer Ag	Pflanzenwachstumsregulierende mittel, verfahren zu ihrer herstellung und ihre verwendung zur regulierung des pflanzenwachstums
US4737323A (en)	1986-02-13	1988-04-12	Liposome Technology, Inc.	Liposome extrusion method
US5093330A (en)	1987-06-15	1992-03-03	Ciba-Geigy Corporation	Staurosporine derivatives substituted at methylamino nitrogen
US5017211A (en)	1987-09-23	1991-05-21	Ciba-Geigy Corporation	Heterocyclic compounds
US5010099A (en)	1989-08-11	1991-04-23	Harbor Branch Oceanographic Institution, Inc.	Discodermolide compounds, compositions containing same and method of preparation and use
KR0166088B1 (ko)	1990-01-23	1999-01-15	.	수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5395855A (en)	1990-05-07	1995-03-07	Ciba-Geigy Corporation	Hydrazones
IL115849A0 (en)	1994-11-03	1996-01-31	Merz & Co Gmbh & Co	Tangential filtration preparation of liposomal drugs and liposome product thereof
NZ334821A (en)	1996-08-30	2000-12-22	Novartis Ag	Method for producing epothilones
AU4141697A (en)	1996-09-06	1998-03-26	Obducat Ab	Method for anisotropic etching of structures in conducting materials
DK0941227T5 (da)	1996-11-18	2009-10-05	Biotechnolog Forschung Gmbh	Epothilon D, dens fremstilling samt dens anvendelse som cytostatisk middel og som plantebeskyttelsesmiddel
US6441186B1 (en)	1996-12-13	2002-08-27	The Scripps Research Institute	Epothilone analogs
GB9721069D0 (en)	1997-10-03	1997-12-03	Pharmacia & Upjohn Spa	Polymeric derivatives of camptothecin
US6194181B1 (en)	1998-02-19	2001-02-27	Novartis Ag	Fermentative preparation process for and crystal forms of cytostatics
IL138113A0 (en)	1998-02-25	2001-10-31	Sloan Kettering Inst Cancer	Synthesis of epothilones, intermediates thereto and analogues thereof
JP4516690B2 (ja)	1998-08-11	2010-08-04	ノバルティスアーゲー	血管形成阻害活性を有するイソキノリン誘導体
NZ511722A (en)	1998-11-20	2004-05-28	Kosan Biosciences Inc	Recombinant methods and materials for producing epothilone and epothilone derivatives
WO2001055115A1 (en)	2000-01-27	2001-08-02	Cytovia, Inc.	Substituted nicotinamides and analogs as activators of caspases and inducers of apoptosis and the use thereof
PE20020354A1 (es)	2000-09-01	2002-06-12	Novartis Ag	Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
WO2003039529A1 (en)	2001-11-07	2003-05-15	4Sc A.G.	Selective antibacterial agents
AU2002367087A1 (en)	2001-12-21	2003-07-15	7Tm Pharma A/S	Method for the treatment of mc receptor related disorders with a chelate and/or a chelator
GB0215676D0 (en) *	2002-07-05	2002-08-14	Novartis Ag	Organic compounds
ES2571779T3 (es)	2002-12-13	2016-05-26	Ym Biosciences Australia Pty	Inhibidores de cinasa a base de nicotinamida
AR043633A1 (es)	2003-03-20	2005-08-03	Schering Corp	Ligandos de receptores de canabinoides
US20070054916A1 (en)	2004-10-01	2007-03-08	Amgen Inc.	Aryl nitrogen-containing bicyclic compounds and methods of use
US20080167347A1 (en)	2005-01-20	2008-07-10	Shiongi & Co., Ltd.	Ctgf Expression Inhibitor
WO2006120178A1 (en)	2005-05-11	2006-11-16	Novo Nordisk A/S	New haloalkylsulfone substituted compounds useful for treating obesity and diabetes
WO2007002441A1 (en)	2005-06-24	2007-01-04	Emory University	Methods of use for non-atp competitive tyrosine kinase inhibitors to treat pathogenic infection
PT1746097E (pt)	2005-07-20	2010-04-15	Aventis Pharma Sa	Heterociclos fundidos de 1,4-di-hidropiridina, processo para a sua preparação, utilização e composições que os contêm
CN102861338A (zh) *	2006-04-05	2013-01-09	诺瓦提斯公司	用于治疗癌症、包含bcr-abl/c-kit/pdgf-r tk抑制剂的组合
WO2008021725A2 (en)	2006-08-11	2008-02-21	Smithkline Beecham Corporation	Chemical compounds
MX2009004141A (es)	2006-10-20	2009-05-01	Irm Llc	Composiciones y metodos para modular receptores de c-kit y pdgfr.
US7939690B2 (en) *	2006-11-15	2011-05-10	High Point Pharmaceuticals, Llc	Haloalkylsulfone substituted compounds useful for treating obesity and diabetes
CN101627027B (zh) *	2007-01-05	2013-06-19	百时美施贵宝公司	氨基吡唑激酶抑制剂
WO2008112695A2 (en)	2007-03-12	2008-09-18	Irm Llc	Pyrazolo [3,4-d] pyrimidines and 1, 2, 5, 6-tetraaza- as- indacenes as protein kinase inhibitors for cancer treatment
WO2008124393A1 (en)	2007-04-04	2008-10-16	Irm Llc	Benzothiazole derivatives and their use as protein kinase inhibitors
WO2008144253A1 (en)	2007-05-14	2008-11-27	Irm Llc	Protein kinase inhibitors and methods for using thereof
AU2008281877A1 (en)	2007-08-02	2009-02-05	F. Hoffmann-La Roche Ag	The use of benzamide derivatives for the treatment of CNS disorders
PE20090705A1 (es)	2007-09-17	2009-07-17	Abbott Lab	Derivados de uracilo en el tratamiento de hepatitis c
EA201001847A1 (ru)	2008-06-11	2011-08-30	Айрм Ллк	Соединения и композиции, применяемые для лечения малярии
CN102227421A (zh)	2008-09-29	2011-10-26	贝林格尔.英格海姆国际有限公司	抗增殖化合物
WO2011008788A1 (en)	2009-07-14	2011-01-20	Dawei Zhang	Fluoro-substituted compounds as kinase inhibitors and methods of use thereof
JP2011057661A (ja)	2009-08-14	2011-03-24	Bayer Cropscience Ag	殺虫性カルボキサミド類
KR101663637B1 (ko)	2009-11-13	2016-10-07	제노스코	키나아제 억제제
JO3634B1 (ar) *	2009-11-17	2020-08-27	Novartis Ag	طريقة لعلاج اضطرابات تكاثرية وحالات مرضية أخرى متوسطة بنشاط كيناز bcr-abl، c-kit، ddr1، ddr2، أو pdgf-r
WO2011082400A2 (en)	2010-01-04	2011-07-07	President And Fellows Of Harvard College	Modulators of immunoinhibitory receptor pd-1, and methods of use thereof
RU2524210C2 (ru)	2010-01-29	2014-07-27	Ханми Сайенс Ко., Лтд.	ПРОИЗВОДНЫЕ ТИЕНО[3,2-d]ПИРИМИДИНА, ОБЛАДАЮЩИЕ ИНГИБИРУЮЩЕЙ АКТИВНОСТЬЮ В ОТНОШЕНИИ ПРОТЕИНКИНАЗЫ
US9464065B2 (en)	2011-03-24	2016-10-11	The Scripps Research Institute	Compounds and methods for inducing chondrogenesis
CN102276500A (zh) *	2011-05-05	2011-12-14	西安交通大学	水杨酰胺类抗肿瘤化合物及其合成方法和用途
US9278910B2 (en)	2011-05-31	2016-03-08	Receptos, Inc.	GLP-1 receptor stabilizers and modulators
CA2871332A1 (en) *	2012-05-15	2013-11-21	Novartis Ag	Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1
WO2013171642A1 (en) *	2012-05-15	2013-11-21	Novartis Ag	Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1
EP2861579B9 (en)	2012-05-15	2018-08-29	Novartis AG	Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1
CN104334529B (zh)	2012-05-15	2017-03-15	诺华股份有限公司	用于抑制abl1、abl2和bcr‑abl1的活性的化合物和组合物

2013
- 2013-05-09 EP EP13730652.8A patent/EP2861579B9/en active Active
- 2013-05-09 GE GEAP201313621A patent/GEP201606532B/en unknown
- 2013-05-09 WO PCT/IB2013/053768 patent/WO2013171639A1/en active Application Filing
- 2013-05-09 AP AP2014007992A patent/AP3613A/xx active
- 2013-05-09 PE PE2014002006A patent/PE20150669A1/es not_active Application Discontinuation
- 2013-05-09 RS RS20180497A patent/RS57177B1/sr unknown
- 2013-05-09 TR TR2018/07023T patent/TR201807023T4/tr unknown
- 2013-05-09 KR KR1020147031773A patent/KR102091893B1/ko active Protection Beyond IP Right Term
- 2013-05-09 MX MX2014013374A patent/MX359014B/es active IP Right Grant
- 2013-05-09 PE PE2020000185A patent/PE20210667A1/es unknown
- 2013-05-09 PL PL13730652T patent/PL2861579T3/pl unknown
- 2013-05-09 CU CUP2014000131A patent/CU24265B1/es unknown
- 2013-05-09 JP JP2015512169A patent/JP6078639B2/ja active Active
- 2013-05-09 SI SI201330997T patent/SI2861579T1/en unknown
- 2013-05-09 PT PT137306528T patent/PT2861579T/pt unknown
- 2013-05-09 BR BR112014026383-3A patent/BR112014026383B1/pt active IP Right Grant
- 2013-05-09 HU HUE13730652A patent/HUE039138T2/hu unknown
- 2013-05-09 NZ NZ701626A patent/NZ701626A/en unknown
- 2013-05-09 ES ES13730652.8T patent/ES2670601T3/es active Active
- 2013-05-09 PE PE2016001014A patent/PE20161416A1/es unknown
- 2013-05-09 CA CA2868958A patent/CA2868958C/en active Active
- 2013-05-09 LT LTEP13730652.8T patent/LT2861579T/lt unknown
- 2013-05-09 DK DK13730652.8T patent/DK2861579T5/da active
- 2013-05-09 MA MA37519A patent/MA37519B1/fr unknown
- 2013-05-09 ME MEP-2018-117A patent/ME03095B/me unknown
- 2013-05-09 MY MYPI2014703394A patent/MY169377A/en unknown
- 2013-05-09 AU AU2013261127A patent/AU2013261127B2/en active Active
- 2013-05-09 EA EA201491824A patent/EA024391B1/ru not_active IP Right Cessation
- 2013-05-09 SG SG11201407152XA patent/SG11201407152XA/en unknown
- 2013-05-09 CN CN201380025539.6A patent/CN104302638B/zh active Active
- 2013-05-13 US US13/892,769 patent/US8829195B2/en active Active
- 2013-05-15 AR ARP130101692A patent/AR091063A1/es active IP Right Grant
- 2013-05-15 UY UY0001034811A patent/UY34811A/es active IP Right Grant
- 2013-05-15 TW TW102117263A patent/TWI560183B/zh active
- 2013-05-15 JO JOP/2013/0150A patent/JO3453B1/ar active
- 2013-09-05 UA UAA201412051A patent/UA113208C2/uk unknown
2014
- 2014-07-31 US US14/448,363 patent/US20140343086A1/en not_active Abandoned
- 2014-09-29 ZA ZA2014/07065A patent/ZA201407065B/en unknown
- 2014-10-13 TN TN2014000427A patent/TN2014000427A1/fr unknown
- 2014-10-14 CL CL2014002757A patent/CL2014002757A1/es unknown
- 2014-11-06 IL IL235566A patent/IL235566A/en active IP Right Grant
- 2014-11-12 DO DO2014000256A patent/DOP2014000256A/es unknown
- 2014-11-13 PH PH12014502531A patent/PH12014502531B1/en unknown
- 2014-11-14 SV SV2014004850A patent/SV2014004850A/es unknown
- 2014-11-14 GT GT201400253A patent/GT201400253A/es unknown
- 2014-11-14 CR CR20140519A patent/CR20140519A/es unknown
- 2014-11-14 CO CO14252517A patent/CO7131380A2/es unknown
2015
- 2015-04-24 HK HK15103981.8A patent/HK1203495A1/xx unknown
2018
- 2018-05-03 HR HRP20180695TT patent/HRP20180695T1/hr unknown
- 2018-05-18 CY CY20181100518T patent/CY1120235T1/el unknown
2022
- 2022-10-20 FR FR22C1053C patent/FR22C1053I2/fr active Active
- 2022-10-25 HU HUS2200046C patent/HUS2200046I1/hu unknown
- 2022-10-25 NO NO2022043C patent/NO2022043I1/no unknown
- 2022-10-26 NL NL301201C patent/NL301201I2/nl unknown
- 2022-11-02 CY CY2022033C patent/CY2022033I1/el unknown
- 2022-11-10 LT LTPA2022523C patent/LTPA2022523I1/lt unknown

Also Published As

Publication number	Publication date
ES2670601T9 (es)	2022-11-30
CY2022033I2 (el)	2023-01-05
BR112014026383A2 (pt)	2017-06-27
CN104302638A (zh)	2015-01-21
ES2670601T3 (es)	2018-05-31
US8829195B2 (en)	2014-09-09
EA201491824A1 (ru)	2015-02-27
FR22C1053I1 (fr)	2022-12-16
PH12014502531A1 (en)	2015-01-12
AP2014007992A0 (en)	2014-10-31
PE20210667A1 (es)	2021-04-05
JP2015521185A (ja)	2015-07-27
KR20150020170A (ko)	2015-02-25
PT2861579T (pt)	2018-04-27
TN2014000427A1 (en)	2016-03-30
IL235566A (en)	2016-09-29
MX2014013374A (es)	2015-01-16
SI2861579T1 (en)	2018-05-31
CY1120235T1 (el)	2019-07-10
KR102091893B1 (ko)	2020-03-23
CN104302638B (zh)	2016-08-24
MA37519B1 (fr)	2017-03-31
WO2013171639A1 (en)	2013-11-21
HUE039138T2 (hu)	2018-12-28
NL301201I2 (nl)	2022-12-07
DK2861579T3 (en)	2018-05-28
EP2861579B1 (en)	2018-02-21
HUS2200046I1 (hu)	2022-11-28
HRP20180695T1 (hr)	2018-06-01
PE20150669A1 (es)	2015-05-17
GEP201606532B (en)	2016-08-25
DK2861579T5 (da)	2022-10-24
ZA201407065B (en)	2016-08-31
NO2022043I1 (en)	2022-10-25
PL2861579T3 (pl)	2018-07-31
US20130310395A1 (en)	2013-11-21
CA2868958C (en)	2020-09-01
BR112014026383B1 (pt)	2020-11-17
CO7131380A2 (es)	2014-12-01
EA024391B1 (ru)	2016-09-30
TR201807023T4 (tr)	2018-06-21
EP2861579A1 (en)	2015-04-22
AR091063A1 (es)	2014-12-30
LT2861579T (lt)	2018-05-10
SV2014004850A (es)	2018-04-04
PE20161416A1 (es)	2017-01-08
PH12014502531B1 (en)	2015-01-12
CR20140519A (es)	2015-03-26
FR22C1053I2 (fr)	2023-11-10
DOP2014000256A (es)	2015-02-27
CU20140131A7 (es)	2015-04-29
SG11201407152XA (en)	2014-11-27
CL2014002757A1 (es)	2015-01-23
NZ701626A (en)	2016-02-26
JP6078639B2 (ja)	2017-02-08
HK1203495A1 (en)	2015-10-30
CY2022033I1 (el)	2023-01-05
ME03095B (me)	2019-01-20
CA2868958A1 (en)	2013-11-21
AP3613A (en)	2016-02-29
TW201400471A (zh)	2014-01-01
JO3453B1 (ar)	2020-07-05
MX359014B (es)	2018-09-12
MY169377A (en)	2019-03-26
CU24265B1 (es)	2017-07-04
IL235566A0 (en)	2015-02-01
EP2861579B9 (en)	2018-08-29
MA37519A1 (fr)	2016-06-30
UA113208C2 (xx)	2016-12-26
AU2013261127A1 (en)	2014-11-20
UY34811A (es)	2013-12-31
AU2013261127B2 (en)	2015-03-12
TWI560183B (en)	2016-12-01
RS57177B1 (sr)	2018-07-31
GT201400253A (es)	2017-09-28
US20140343086A1 (en)	2014-11-20

Publication	Publication Date	Title
LTPA2022523I1 (lt)	2022-12-12
BR112014022562A2 (lt)	2017-08-22
BR112014017592A2 (lt)	2017-06-20
BR112014017659A2 (lt)	2017-06-20
BR112014017646A2 (lt)	2017-06-20
BR112014017638A2 (lt)	2017-06-20
AR092201A1 (lt)	2015-04-08
BR112014018648A2 (lt)	2017-06-20
BR112014017607A2 (lt)	2017-06-20
BR112013027865A2 (lt)	2017-01-03
BR112014017634A2 (lt)	2017-06-20
BR112014017609A2 (lt)	2017-06-20
BR112014017644A2 (lt)	2017-06-20
BR112014018986A2 (lt)	2017-06-20
BR112014017588A2 (lt)	2017-06-20
BR112014017647A2 (lt)	2017-06-20
BR112014025519A2 (lt)	2017-08-15
BR112014013184A8 (lt)	2017-06-27
BR112014017630A2 (lt)	2017-06-20
BR112014017652A2 (lt)	2017-06-20
BR112014017641A2 (lt)	2017-06-20
BR112014017636A2 (lt)	2017-06-20
BR112014017667A2 (lt)	2017-06-20
BR112014017600A2 (lt)	2017-06-20
BR112014017671A2 (lt)	2017-06-20